Health ❯ Healthcare ❯ Pharmacology ❯ Drug Therapy

Combination Therapy

Padcev–Keytruda Cuts Recurrence and Death Risk in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

The companies plan regulatory discussions after presenting the late-stage results at ESMO.

Phase 3 Trial Finds Tukysa Improves PFS in First-Line Maintenance for HER2-Positive Metastatic Breast Cancer